Iniparib efficacy end point was the change from baseline in the total nasal symptom score . The mean reduction from baseline in TNSS was significantly greater with azelastinepared with placebo . Significant improve-ments in individual symptom scores were also observed . The spray dosage was well tolerat with fewer patients reporting either somnolence or bitter tast pared with the labeled incidences of and , respective for sprays per nostril twice daily. A new formulation of azelastine nasal spray was recently approved by the Food and Drug Administratio but subsequent trials in patients with NAR reported lower incidences that were not statistically different from placebo .

As indicated in Table , the incidence of somnolence was reduced even further by Cladribine decreasing the dos-age from sprays to spray per nostril. The decreased dosage also was associated with less bitter taste. The new formulation of azelastine nasal spray in gener better tolerated by patients than the original formulatio with fewer reports of bitter taste and nasal di-fort . OLOPATADINE Olopatadine is an antihistamine that selectively blocks the H receptor and has also been shown to inhibit the release of histamine and other proinflammatory mediators from Figure . Percent reduction from baseline in mean reflective nasal symptom scores after weeks of treatment in patients with seasonal allergic rhinitis in studies of azelastine nasal spr , administered spray per nostril twice daily. TNSS indicates total nasal symptom score; nasal congestion; nasal  purchase Chlorogenic acid itching; sneezing; and rhinorrhea. VOLUME , NOVEMB Table .

Number of Adverse Events With Azelastine Nasal Spr , and Olopatadine Nasal Spr Azelastine nasal spr Azelastine nasal spr Olopatadine nasal spr Adverse events Astepro Astelin Vehicle Astepro Astelin Vehicle Patanase Vehicle Bitter taste Headache order Ferulic acid Somnolence Epistaxis Nasal burning mast cells. In the conjuncti olopatadine has been olopatadine at all time point. statistical superiority to antihistaminic activity. In the no olopatadine has been mometasone was demonstrated at of time shown to produce significant reductions in the release of lysozy histami and albumin induced by nasal aller-gen provocation. The onset and duration of action of olopatadine nasal spray were exam-ined in patients with SAR exposed to ragweed allergen in an EEC. ared with place all concentrations of olopatadine reduced the TNSS at minutes. Statistical significance vs placebo was attained with olopatadine na-points.

Efficacy Two -week multicenter studies evaluated the efficacy of olopatadine nasal spray  oxidation  to treat SAR symptoms during the pollen season in patients. Patients received olopata-di or , or a vehicle placebo administered as sprays per nostril twice daily for weeks.pared with sal spr , at all time points from place olopatadi , produced statistically significant minutes through hours after dosing. These results were verified in another EEC study that examined the onset and duration of action of olopatadine nasal spr ,-improvements in AR symptoms as evaluated by both reflec-tive TNSS and instantaneous TNSS. Significant im-provements were also reported for ocular symptoms and daily pared with mometasone furoate nasal spr g, and functioning as measured.